The website may be down at times on Saturday, December 14, and Sunday, December 15, for maintenance. 

  • Diabetes Outcome Study

    Study Description and Methods

    In this study, we wanted to describe how primary care clinicians care for patients with type 2 diabetes. This was a descriptive study of predictors of glycemic control of patients with type 2 diabetes mellitus. Physicians from the Minnesota Academy of Family Physicians Research Network (MAFPRN) and two networks in Texas also participated.

    Specific Aims and Objectives

    Our specific aims were:

    1. To describe the outcomes of type 2 diabetes achieved by primary care physicians and their patients; and
    2. To identify the major patient, physician, and practice characteristics that are associated with varying levels of glycemic control and health-related quality of life indicators.

    Timeline

    This study was conducted from February 2001 through April 2002.

    Status

    This project is closed. See below for key findings and publications.

    Presentations

    S.J. Spann, J.M. Galliher, R.J. Volj, J. Hickner. “Diabetes Outcome Study: Final Report and Presentation”. Eli Lilly and Company, Indianapolis, IN. Oct 10, 2002.

    Stephen J. Spann, MD. “Diabetes Outcome Study: Physician and Patient Characteristics”. NAPCRG Presentation.

    Robert J. Volk, PhD. “The Diabetes Outcome Study: A Progress Report”. Convocation 2002.

    Key Findings and Publications

    Only modest numbers of patients achieve established targets of diabetes control. Reengineering primary care practice may be necessary to substantially improve care.

    Access the complete manuscript:

    Management of Type-2 Diabetes in the Primary Care Setting:  A Practice-Based Research Network Study. Spann SJ, Nutting PA, Galliher JM, et al. Ann Fam Med 2006;4:23-3.

    Contact Information

    For additional information about this study, please contact:

    AAFP National Research Network
    1-800-274-2237 x3180
    nrn@aafp.org

    This study was funded by grants from Eli Lilly and Company.